The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN testicular cancer practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network; 2003.
2.
ShelleyM.D., BurgonK., MasonM.D.Treatment of testicular germ-cell cancer: A Cochrane evidence-based systematic review.Cancer Treat Rev.2002; 28: 237–53.
3.
WilliamsS.D., BirchR., EinhornL.H.Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.N Engl J Med.1987; 316: 1435–40.
4.
de WitR., StoterG., SleijferD.T.Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC genitourinary tract cancer cooperative group.Br J Cancer.1995; 71: 1311–4.
5.
BokemeyerC., KohrmannO., TischlerJ.A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good-risk metastatic nonseminomatous germ cell tumors.Ann Oncol.1996; 7: 1015–21.
6.
de WitR., StoterG., KayeS.B.Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.J Clin Oncol.1997; 15: 1837–43.
7.
de WitR., RobertsJ.T., WilkinsonP.M.Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5- day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Cancer Cooperative Group and the Medical Research Council.J Clin Oncol.2001; 19: 1629–40.
8.
TonerG.C., StocklerM.R., BoyerM.J.Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: A randomised trial. Australian and New Zealand Germ Cell Trial Group.Lancet.2001; 357: 739–45.
9.
de WitR., StoterG., SleijferD.T.Four cycles of BEP vs four cycles of VIP in patients with intermedicate-prognosis metastatic testicular nonseminoma: A randomized study of the EORTC genitourinary tract cancer cooperative group.Br J Cancer.1998; 73: 828–32.
10.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
11.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
12.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network; 2003.
13.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
14.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol Oncol.1993; 50: 147–158.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
20.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6: 145–151.
21.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36(suppl 1): S15–S21.
22.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49: 1796–9.
23.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–402.
24.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–74.
25.
StephensonW.T., PoirierS.M., RubinL.Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin.J Clin Oncol.1995; 13: 2278–80.
26.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., ed. The Chemotherapy Sourcebook.3rd ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.
27.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
28.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–89.
